Unstructured Recombinant Polymers Extend Serum Half-Life
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for modifying proteins with polymers, such as PEGylation, face challenges including complex multi-step processes, product mixture separation, and limitations in site-specific attachment, leading to reduced therapeutic activity and immunogenicity concerns, especially with pathogen-derived sequences.
Innovation Solution
The development of unstructured recombinant polymers (URPs) comprising at least 200 contiguous amino acids with a high percentage of glycine, aspartate, alanine, serine, threonine, glutamate, and proline residues, which are designed to minimize non-specific binding and enhance serum stability and solubility, allowing for the creation of multidomain proteins with extended serum half-life and reduced immunogenicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If chemical conjugation of polymers to proteins is performed, then serum half-life is extended, but the process becomes complex and requires multi-step procedures
Solution Approach 1:
The polymer is genetically fused to the protein before expression, eliminating the need for post-purification conjugation steps. The fusion protein is directly expressed and purified in a single step, resolving the contradiction between extending serum half-life and reducing process complexity.
Solution Approach 2:
The polymer and protein are combined into a single genetic construct that is co-expressed as a fusion protein. This merging eliminates separate conjugation steps and simplifies the overall manufacturing process while maintaining the serum half-life extension benefit.
2Reliability
If site-specific PEGylation is performed, then therapeutic activity is maintained, but the process requires careful control and has difficulty eliminating side reactions
Solution Approach 1:
The chemical conjugation process is replaced with a genetic fusion approach. Instead of using chemical reagents and controlling complex reaction conditions, the polymer-protein linkage is established through genetic coding, eliminating side reactions and simplifying process control while maintaining therapeutic activity.
3Duration of action of stationary object
If pathogen-derived sequences are used for polymer modification, then serum half-life is extended, but immunogenicity increases
Solution Approach 1:
The polymer sequence is engineered with specific local characteristics - using repetitive sequences with low information content that mimic host proteins. This local quality modification extends serum half-life while reducing immunogenicity by making the polymer appear more 'self-like' to the immune system.
Solution Approach 2:
The sequence parameters of the polymer are optimized by using repetitive amino acid sequences with specific compositional characteristics. These parameter changes (sequence composition, repetitiveness, low information content) simultaneously extend serum half-life and reduce immunogenicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
URPs significantly increase the serum half-life and solubility of proteins, reduce immunogenicity, and improve manufacturing and characterization by forming stable, non-aggregating products with enhanced therapeutic properties.
Implementation Method 1
These polymers exert their effect by increasing the hydrodynamic radius (also called Stokes' radius) of the modified protein relative to the unmodified protein, which reduces the rate of clearance by kidney filtration
Implementation Method 2
In addition, polymer attachment can reduce interaction of the modified protein with other proteins, cells, or surfaces
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention provides unstructured recombinant polymers (URPs) and proteins containing one or more of the URPs. The present invention also provides microproteins, toxins and other related proteinaceous entities, as well as genetic packages displaying these entities. The present invention also provides recombinant polypeptides including vectors encoding the subject proteinaceous entities, as well as host cells comprising the vectors. The subject compositions have a variety of utilities including a range of pharmaceutical applications.